Previous 10 | Next 10 |
2023-05-15 17:56:10 ET Biondvax Pharmaceuticals press release ( NASDAQ: BVXV ): Q1 GAAP EPS of $0.00 beats by $0.73 . As of March 31, 2023, BiondVax had cash and cash equivalents of $10.9 million as compared to $14.2 million as of December 31, 2022. The decrease i...
JERUSALEM, ISRAEL / ACCESSWIRE / May 15, 2023 / (via IBN) -- BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, tod...
New research has found that one in every ten people in the United Kingdom suffers from an autoimmune illness. Autoimmune illnesses usually develop when the body’s immune system starts to attack normal cells, destroying healthy tissues in the body. While experts don’t know the e...
New research has found broad-spectrum antiviral agents that could target RNA virus families that pose substantial threats for future outbreaks. The research was led by Gustavo Garcia Jr. of the Molecular and Medical Pharmacology department at the University of California, Los Angeles. It focuse...
New research has determined that the first signs of rheumatic disease may show up on an individual’s skin. Rheumatic disease is a term referring to conditions such as arthritis , which affect the tendons, joints, muscles, bones and/or ligaments. The study was carried out by a UT Southwe...
Data management is a critical component of the healthcare industry. It helps clinicians to improve patient care; improves communication between patients, healthcare providers, and stakeholders; and allows physicians to make data-driven decisions. Health data management also plays a role in inte...
BiondVax intends to expand its contract development and manufacturing organization (“CDMO”) offering as it continues the primary focus on its NanoAb pipeline development The CDMO services include aseptic fill and finish, upstream and downstream process development, as well as anal...
Scientists may have identified a pair of epilepsy syndrome patterns and their link to autoimmune illnesses. The single-center study was carried out between January 2016 and December 2020 and involved patients at a tertiary epilepsy center. During this period, the researchers gathered data fro...
The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK, and Bristol-Myers Squibb The team has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influ...
BiondVax (NASDAQ: BVXV) , a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, was featured in an equity research report published by Aegis Capital Corp. In the rep...
News, Short Squeeze, Breakout and More Instantly...
BiondVax Pharmaceuticals Ltd. Company Name:
BVXV Stock Symbol:
NASDAQ Market:
BiondVax (NASDAQ: BVXV) , a biotechnology company, today announced a change of its corporate name to Scinai Immunotherapeutics, which will debut on the Nasdaq under a new symbol, SCNI, on Sept. 7, 2023. In the past two years, the company has revamped its senior management team and pharmaceuticals...
JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) , a biopharmaceutical company, is pleased to announce today a change of its corporate name to Scinai Immunotherapeutics Ltd. (“Scinai ”). In the past two years, the Company ...
BiondVax (NASDAQ: BVXV) , a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently recei...